Strive Financial Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Strive Financial Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$987	Buy	+4	New	+$1.02K	﹤0.01%	1053

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Strive Financial Group's ALNY Position: Q3 2026 in Review

Strive Financial Group opened a new position in Alnylam Pharmaceuticals (ALNY) in Q3 2026: 4 shares worth $987. The stake represents ﹤0.01% of the portfolio and ranks #1053 among its holdings.

403 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

Strive Financial Group held 4 shares of Alnylam Pharmaceuticals worth $987 as of Q3 2026.
Alnylam Pharmaceuticals was a new Strive Financial Group position in Q3 2026.
Alnylam Pharmaceuticals made up ﹤0.01% of Strive Financial Group's portfolio in Q3 2026, its #1053 holding.
403 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Strive Financial Group's 13F filing for Q3 2026, filed 9 Nov 2026.